View Author
Camps, M.H.
( M.H. Camps)
fcgriib oc use study agreement fcgriibb fcgriib 1292/2 mice fcgriibb 62/2 mice prescriber control women 1292/2 62/2 sle 16 locus locus cancer strain duration breast phenotype result brand disease information table case-control brand names kidney development month case-control study fcgr 2b gene period autoimmunity susceptibility group 12 mo 129- titer history b 6 mice c 57bl region netherland kruskal –wallis test preparation breast cancer mouse record misclassification brand name difference background woman polymorphism fcgriibb 62/2 strain fcgriib 2/2 mice receptor b 6 genome c 57bl mice c 57bl background c 3 deposition signi fcgriii 1292/2 mice fcgriii arthritis interview autoantibody titers epistatic interactions t test +++ anking b cells yaa locus immunology kidney pathology study population oc histories *** center 0.001
2 Most Recent Publications
|
The inhibiting Fc receptor for IgG, FcγRIIB, is a modifier of autoimmune susceptibility
(Article)
Boross, P. Arandhara, V.L. Lubberts, E.W. Salvatori, D.C.F. Rastaldi, M.P. Ossendorp, F. Daha, M.R. Cook, H.T. Izui, S. Botto, M. Verbeek, J.S. Martin-Ramirez, J. Santiago-Raber, M.L. Carlucci, F. Flierman, R. Kaa, J. van der Breukel, C. Claassens, J.W. Camps, M.H. |
2011-08-01
|
|
Agreement between oral contraceptive users and prescribers: implications for case-control studies
(Article)
Leeuwen, F.E. van Duijn, C.M. van Camps, M.H. Kempers, B.A. Mentjens, M.F. Mulder, H.B. Schouten, E.G. Zwijsen, R.M.L. Rookus, M.A. |
1992-01-01
|
